IR for the long-cycle, milestone-led register.
Biotech is the ASX sector where the gap between operational reality and share-price reaction is widest. Trial readouts, regulatory milestones, and partnership announcements have to be communicated with absolute care under Listing Rule 3.1 — and in a way that survives twelve months of milestone-quiet periods. Orca runs IR for listed biotech, med-tech, and diagnostics companies inside that constraint.
Biotech & life sciences
Pre-revenue biotech, med-tech, and diagnostics
The ASX biotech sector spans pre-revenue platforms, post-approval commercial stories, and diagnostics — each with its own communications discipline.
What makes the IR work in this sector hard.
Every sector has the disclosure quirks that catch a generalist firm out. The ones we see most in biotech & life sciences:
Milestone-led cadence
Trial readouts and regulatory decisions move the price and the narrative. The disclosure machinery has to be ready, not improvised.
Scientific translation
Endpoints, p-values, hazard ratios — written so a generalist fund manager and a sector specialist both read the same conclusion.
Capital between milestones
Pre-revenue biotechs raise repeatedly. The IR work between raises is what makes the next raise possible.
Partnership and licensing comms
Deal terms, milestone payments, royalty structures — communicated to satisfy both the counterparty confidentiality and disclosure obligations.
What we deliver into biotech & life sciences.
Clinical & regulatory announcement framework
Pre-built templates, sign-off chain, and language library so trial readouts and FDA/TGA decisions can be lodged within hours of receipt.
Capital raise communications
Placement, entitlement offer, SPP, and strategic-equity comms — tuned to the milestone calendar.
Partnership & licensing comms
Drafting and ASX lodgement of partnership, licensing, and milestone-payment announcements alongside legal and the partner's communications team.
Investor day & KOL programs
Investor days, KOL panels, and the long-form materials that build conviction through the quiet periods.
Where we typically engage.
The recurring announcement and milestone events that shape the sector calendar.
- Clinical trial readouts — Phase I, II, III
- FDA, TGA, EMA approvals and decisions
- Partnership and licensing deals
- Capital raises around milestones
- Strategic reviews and M&A
Services we run most often in this sector.
Company Announcements
ASX announcements drafted, designed, and lodge-ready for small-mid cap companies — clearer, sharper, better-looking. Reviewed for consistent messaging and sequenced around your milestones.
Competitor Analysis
A tailored competitor and sector report, delivered weekly — peer announcements, share-price moves, and sector signals, synthesised by purpose-built AI into decision-ready reporting for your board.
PR Strategy and Tactics
Proactive PR and media strategy for small-mid cap ASX companies — a differentiated corporate narrative, media interviews and features, investor briefings, and crisis communication.
Frequently asked.
Do you have medical or scientific staff?
No — we work alongside your scientific advisory and chief medical officer. Our seat is the communications translation, not the science.
Can you handle a confidential trial readout?
Yes — that is a core part of the discipline. We have drafted dozens of trial-readout announcements under embargo.
Talk to us about biotech & life sciences.
Tell us about your company and where you want the market to be. We will take it from there.